New Zealand markets open in 7 hours 51 minutes

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.98+0.26 (+2.98%)
At close: 04:00PM EST
8.90 -0.08 (-0.89%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.72
Open8.44
Bid6.00 x 1400
Ask9.60 x 1100
Day's range8.04 - 9.04
52-week range8.04 - 37.07
Volume1,452,260
Avg. volume899,637
Market cap381.848M
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)-3.28
Earnings date22 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est41.00
  • Simply Wall St.

    Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

    RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January. G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January

  • GlobeNewswire

    G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), and an aggregate of 50,200 shares of G1’s common stock to seven employees under the previously-announced G1 Therapeutics, Inc.